Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

It is finally bouncing back after several challenging years.

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a positive opinion for its Keytruda (pembrolizumab) and Pad ...

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its famous ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Merck & Co., Inc.

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than ...

CHONGQING, CHINA - JULY 27: In this photo illustration, a person holds a smartphone displaying the logo of Merck & Co., Inc. (NYSE: MRK), a leading American multinational pharmaceutical company, with ...

View Merck & Co., Inc. MRK stock quote prices, financial information, real-time forecasts, and company news from CNN.

New ASCO data boosted the case for Ivonescimab as a potential challenger to Merck's blockbuster cancer drug Keytruda. ・Phase ...